Description
Mizoribine is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) that exhibits immunosuppressive and, potentially, antifungal activities. Mizoribine is used clinically in organ transplantations and to treat rheumatoid arthritis and lupus. In synovial cells, mizoribine decreases levels of IL-6 and matrix metalloproteinase 1 (MMP1). Mizoribine also inhibits proliferation of mesangial cells, decreasing expression of cyclin D1, skp2, and CDK2; it also increases expression of p27. Additionally, this compound may decrease proliferation of species of Candida and Aspergillus.
References
Sugiyama E, Ikemoto M, Taki H, et al. Mizoribine, an inhibitor of inosine monophosphate dehydrogenase, inhibits interleukin-6 production by freshly prepared rheumatoid synovial cells. Mod Rheumatol. 2001 Mar;11(1):28-33. PMID: 24387017.
Liu S, Xie Y, Lv Y, et al. A novel target of mizoribine inhibiting mesangial cell proliferation: S phase kinase-associated protein 2. Am J Nephrol. 2010;32(5):447-55. PMID: 20924167.
Rodriguez-Suarez R, Xu D, Veillette K, et al. Mechanism-of-action determination of GMP synthase inhibitors and target validation in Candida albicans and Aspergillus fumigatus. Chem Biol. 2007 Oct;14(10):1163-75. PMID: 17961828.
Zhong B, Tajima M, Takahara H, et al. Inhibitory effect of mizoribine on matrix metalloproteinase-1 production in synovial fibroblasts and THP-1 macrophages. Mod Rheumatol. 2005;15(4):264-8. PMID: 17029075.
Hedstrom L. IMP dehydrogenase: mechanism of action and inhibition. Curr Med Chem. 1999 Jul;6(7):545-60. PMID: 10390600.
